Kyntra Bio (KYNB) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 19 200 sessions, January 8, 2026 to October 23, 2026
- Largest daily move
- -12.3% close of October 23, 2026
- 1-month change
- -36.8% closing prices, September 23, 2026 to October 23, 2026
Company Description
Kyntra Bio, Inc. is a biopharmaceutical company that develops therapies for oncology and rare disease indications. The company, formerly known as FibroGen, trades on Nasdaq under the symbol KYNB and is headquartered in San Francisco, California. Its disclosed programs center on roxadustat for anemia-related indications and FG-3246, an antibody-drug conjugate program for metastatic castration-resistant prostate cancer.
Kyntra Bio's pipeline includes roxadustat, marketed in some countries as 爱瑞卓® and EVRENZO™, which is approved in Europe, Japan, China and numerous other countries for the treatment of anemia in chronic kidney disease patients on dialysis and not on dialysis. The company continues to evaluate development of roxadustat in the United States for anemia associated with lower-risk myelodysplastic syndromes, or LR-MDS. This program places Kyntra Bio within the hematology and rare disease areas of drug development while building on an approved molecule outside the United States for CKD anemia.
The company's oncology program is built around FG-3246, also known as FOR46, a first-in-class antibody-drug conjugate targeting CD46. FG-3246 is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Kyntra Bio also reports an associated biomarker program, FG-3180, a CD46-targeted PET imaging agent intended to support the FG-3246 development program.
Kyntra Bio's operating model is that of a clinical-stage and development-focused biotechnology company. Its recurring activities include clinical development, regulatory interactions, data presentations at medical conferences, and financial reporting tied to research and development spending. The company's public disclosures also reflect its transition from the former FibroGen identity to Kyntra Bio and its focus on a narrower set of oncology and rare disease assets.
As a public biotechnology issuer, Kyntra Bio's corporate record includes updates on pipeline development, quarterly and annual financial results, proxy governance matters, equity compensation, and Nasdaq listing compliance. These disclosures document both the scientific focus of its drug candidates and the capital, governance, and reporting requirements associated with a development-stage public biopharmaceutical company.
Stock Performance
Kyntra Bio (KYNB) closed at $4.58 on October 23, 2026. Over the past month, the price has lost 36.8%.
KYNB Metrics & Rankings
Price returns through October 23, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Kyntra Bio has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include management, earnings, earnings date. View all KYNB news →
SEC Filings
Kyntra Bio has filed 10 recent SEC filings, including 4 Form 8-K, 3 Form 4, 1 Form 3, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on October 6, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KYNB SEC filings →
Financial Highlights
Kyntra Bio generated $6.4M in revenue in FY2025, retaining a 91.4% gross margin, operating income reached -$45.9M, and net income was $183.5M. Diluted earnings per share stood at $45.37. The company generated -$4.8M in operating cash flow. The current ratio was 3.39, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Kyntra Bio (KYNB) currently stands at 100.0 thousand shares, down 0.7% from the previous reporting period, representing 2.5% of the float. Since January 2026, short interest has decreased by 13.1%.
Days to Cover History
Days to cover for Kyntra Bio (KYNB) currently stands at 3.7 days, down 12% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since January 2026, the figure has decreased by 29%. Across the settlements charted above, it has ranged from 2.3 to 17.7 days.
KYNB Company Profile & Sector Positioning
Kyntra Bio (KYNB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.